Remodulin® (treprostinil)
Behind you all the way.
Our team will work with your patients to identify any potential obstacles to access and affordability and how we may be able to assist with overcoming them.
Start a referral.
Referral form
To start your patients on Remodulin® (treprostinil) and help them enroll in United Therapeutics Cares™, work with them to complete the referral form and fax it to 1-800-380-5294.
Download referral form
Electronic prescription
If you prefer, you can also prescribe electronically with iAssist. To get started, follow these simple steps:
- Follow the 3-step registration process
- Set up users for the account
- Go to the Start Now section on your dashboard
- Search for Remodulin®
Step 1
Education & Expectations
Upon enrollment, the Patient Navigator will introduce your patient to our program offerings, and establish an appropriate check-in schedule. They will be there to help answer questions your patient may have regarding the safe and effective use of their United Therapeutics treatment and review what to expect in their treatment journey.
Step 2
Coverage & Reimbursement
United Therapeutics Cares will educate your office on the benefits investigation process, including the requirements for prior authorizations and appeals. For patients, we’ll walk through the ins and outs of the insurance landscape and where their specific plan fits in.
Benefits investigations
Our Patient Navigators will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.
Benefits investigations
Our Patient Navigators will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Step 3
Cost & Savings
If a patient is in need of financial assistance to cover the remaining out-of-pocket costs of their prescription, their Patient Navigator can connect them with one of our Access & Affordability Specialists who can provide information on options that may be available to them.
Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per month for Remodulin®. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the annual maximum benefit.*
Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per month for Remodulin®. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the annual maximum benefit.*
Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.
Patient Assistance Program (PAP)
If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.
Patient Assistance Program (PAP)
If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.
Additional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.
Additional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.
Step 4
Prescription Coordination
Once all benefits have been verified and financial assistance options are reviewed, the Patient Navigator will walk your patient through getting set up with their Specialty Pharmacy. The Specialty Pharmacy will work directly with your patient to coordinate any final prescription details and confirm shipping preferences.
This is how Specialty Pharmacies work:
- Your Specialty Pharmacy will conduct a review of your patient’s insurance benefits.
- Your Specialty Pharmacy will confirm your patient’s medication coverage.
- Your Specialty Pharmacy will call your patient to review co-payment and insurance coverage.
- Shipments will be scheduled for delivery where it’s most convenient for your patient.
Our Remodulin® (treprostinil) Specialty Pharmacy network and Specialty Distributor
Step 5
Treatment Support
After working with your patients to determine how often it’s helpful for us to be in touch, the Patient Navigator will set up regular check-ins. This is an opportunity for United Therapeutics Cares to share important information about your patient’s therapy journey and connect them with additional education or resources as needed.
Education specialists
Our Patient Education Specialists are available to work with your patients one-on-one to provide education on their condition and answer questions about the safe and effective use of their United Therapeutics therapy.
Get to know them
Support organizations
There are organizations that understand your patient’s condition and have firsthand experience to help them through their treatment journey.
Explore the communityLooking for additional resources?
Patients deserve ready access to education and support. That’s why we offer a suite of resources, including treatment-specific brochures, to offer education anytime your patient may need it.
See all resourcesFor you:
Browse our full resource library.
Explore resourcesPlease see below for Important Safety Information
WARNINGS AND PRECAUTIONS
- Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
- Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
- Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
IMPORTANT SAFETY INFORMATION FOR REMODULIN
WARNINGS AND PRECAUTIONS
- Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
- Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
- Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
- Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
- Remodulin inhibits platelet aggregation and increases the risk of bleeding.
ADVERSE REACTIONS
- In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).
DRUG INTERACTIONS
- Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
SPECIFIC POPULATIONS
- In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
- Safety and effectiveness of Remodulin in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
INDICATION
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.
Please see accompanying Full Prescribing Information for Remodulin.
For additional information, visit www.RemodulinPro.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).
REMISIhcpMAY2021